Swayze Eric

SEC source: 0000874015-24-000229 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 157

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

SEC source: 0000874015-24-000229 · edgardoc.xml · derivative · entry 4

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 426

Underlying: Common Stock · 125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000229 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 210

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-24-000221 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,907

F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 30, 2024. These shares may not be sold until February 28, 2025.

SEC source: 0000874015-24-000126 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · Officer Level 14

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,929

F1 · kind: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 29, 2024. These shares may not be sold until August 31, 2024.

SEC source: 0000874015-24-000110 · edgardoc.xml · nonDerivative · entry 3

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,324

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Performance restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.55 to $49.57 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-24-000196 · primary_doc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,291

F1 · shares: The original Form 4 filed on February 2, 2024 reported 1,907 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Swayze.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.55 to $49.57 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

F1 · balance_after: The original Form 4 filed on February 2, 2024 reported 1,907 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Swayze.

SEC source: 0000874015-24-000110 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,231

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.

SEC source: 0000874015-24-000110 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,516

SEC source: 0000874015-24-000078 · edgardoc.xml · nonDerivative · entry 4

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 85

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.43, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-24-000078 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,289

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.43, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-24-000078 · edgardoc.xml · derivative · entry 6

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 551

Underlying: Common Stock · 21 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000078 · edgardoc.xml · derivative · entry 5

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,728

Underlying: Common Stock · 17,069 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000078 · edgardoc.xml · nonDerivative · entry 3

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 94

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F4 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-24-000078 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,585

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-24-000058 · edgardoc.xml · derivative · entry 3

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 572

Underlying: Common Stock · 116 shares

Expires not disclosed

F6 · security: Grant to reporting person's son of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000058 · edgardoc.xml · derivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,797

Underlying: Common Stock · 20,400 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000058 · edgardoc.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,482

Underlying: Common Stock · 17,000 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-24-000026 · edgardoc.xml · derivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 154

Underlying: Common Stock · 154 shares

Expires 2034-01-01

F2 · derivative.exercise_date: Grant on 01/02/2024 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000026 · edgardoc.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,200

Underlying: Common Stock · 27,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000006 · edgardoc.xml · derivative · entry 4

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,100 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000006 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,516

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $50.50 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.

SEC source: 0000874015-24-000006 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,616

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-23-000203 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 73

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

SEC source: 0000874015-23-000203 · edgardoc.xml · derivative · entry 4

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 456

Underlying: Common Stock · 125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000203 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 125

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-23-000115 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,516

F1 · kind: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28, 2023. These shares may not be sold until August 28, 2023.

SEC source: 0000874015-23-000096 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,941

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.52 to $40.90 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-23-000096 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,756

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.

SEC source: 0000874015-23-000069 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,041

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.66965 to $39.79044 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-23-000069 · edgardoc.xml · derivative · entry 3

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,397

Underlying: Common Stock · 15,780 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000069 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,672

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-23-000050 · edgardoc.xml · derivative · entry 3

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Indirect · by Son

Disclosed balance after: 581

Underlying: Common Stock · 81 shares

Expires not disclosed

F6 · security: Grant to reporting person's son of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000050 · edgardoc.xml · derivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,177

Underlying: Common Stock · 17,207 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000050 · edgardoc.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,482

Underlying: Common Stock · 14,338 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_date: Represents an award of performance based restricted stock units ("PRSUs"). The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: Represents an award of performance based restricted stock units ("PRSUs"). The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-23-000018 · edgardoc.xml · derivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Indirect · by Son

Disclosed balance after: 108

Underlying: Common Stock · 108 shares

Expires 2033-01-02

F2 · derivative.exercise_date: Grant on 01/03/2023 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/03/2023. 25% of the shares subject to the option will vest and become exercisable on 01/03/2024. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-23-000018 · edgardoc.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,942

Underlying: Common Stock · 22,942 shares

Expires 2033-01-02

F1 · derivative.exercise_date: Grant on 01/03/2023 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/03/2023. 25% of the shares subject to the option will vest and become exercisable on 01/03/2024. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-22-000163 · edgardoc.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Indirect · by Son

Disclosed balance after: 500

Underlying: Common Stock · 500 shares

Expires not disclosed

F1 · security: Grant to reporting person's son of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-22-000159 · edgardoc.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Indirect · by Son

Disclosed balance after: 1,000

Underlying: Common Stock · 1,000 shares

Expires 2032-09-18

F1 · derivative.exercise_date: Grant on 9/19/2022 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 9/19/2022. 25% of the shares subject to the option will vest and become exercisable on 9/19/2023. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-22-000157 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,892

F1 · kind: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 20, 2019.

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 20, 2019.

SEC source: 0000874015-22-000149 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,352

F1 · kind: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 20, 2019.

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 20, 2019.

SEC source: 0000874015-22-000101 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,353

F1 · kind: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 20, 2019.

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 20, 2019.

SEC source: 0000874015-22-000091 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,731

F1 · kind: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28, 2022. These shares may not be sold until August 28, 2022.

SEC source: 0000874015-22-000050 · edgardoc.xml · derivative · entry 3

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,970

Underlying: Common Stock · 13,809 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-22-000050 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,110

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-22-000050 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,104

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-22-000040 · edgardoc.xml · derivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,779

Underlying: Common Stock · 14,859 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-22-000040 · edgardoc.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,144

Underlying: Common Stock · 11,144 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated.

F2 · derivative.exercise_date: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-22-000016 · edgardoc.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,718

Underlying: Common Stock · 29,718 shares

Expires 2032-01-02

F1 · derivative.exercise_date: Grant on 01/03/2022 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/03/2022. 25% of the shares subject to the option will vest and become exercisable on 01/03/2023. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-21-000070 · edgar.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,295

F1 · kind: Reporting 460 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 26, 2021. These 460 shares may not be sold until August 26, 2021.